$1.43
Marinus Pharmaceuticals is a biotechnology business based in the US. Marinus Pharmaceuticals shares (MRNS) are listed on the NASDAQ and all prices are listed in US Dollars. Marinus Pharmaceuticals employs 165 staff and has a trailing 12-month revenue of around $30.3 million.
Our top picks for where to buy Marinus Pharmaceuticals stock
How to buy Marinus Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – MRNS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Marinus Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Marinus Pharmaceuticals stock price (NASDAQ: MRNS)
Use our graph to track the performance of MRNS stocks over time.Marinus Pharmaceuticals shares at a glance
Latest market close | $1.43 |
---|---|
52-week range | $1.05 - $11.26 |
50-day moving average | $1.32 |
200-day moving average | $5.33 |
Wall St. target price | $7.22 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-2.66 |
Is it a good time to buy Marinus Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Marinus Pharmaceuticals price performance over time
Historical closes compared with the close of $1.43 from 2024-09-03
1 week (2024-08-28) | 2.88% |
---|---|
1 month (2024-08-02) | 10.00% |
3 months (2024-06-04) | -0.69% |
6 months (2024-03-04) | -85.01% |
1 year (2023-09-01) | -80.98% |
---|---|
2 years (2022-09-02) | -78.20% |
3 years (2021-09-03) | 12.2 |
5 years (2019-09-04) | 6.24 |
Marinus Pharmaceuticals financials
Revenue TTM | $30.3 million |
---|---|
Gross profit TTM | $-55,943,000 |
Return on assets TTM | -57.75% |
Return on equity TTM | -2986.55% |
Profit margin | 0% |
Book value | $-0.86 |
Market Capitalization | $77.1 million |
TTM: trailing 12 months
Marinus Pharmaceuticals share dividends
We're not expecting Marinus Pharmaceuticals to pay a dividend over the next 12 months.
Have Marinus Pharmaceuticals's shares ever split?
Marinus Pharmaceuticals's shares were split on a 1:4 basis on 22 September 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marinus Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Marinus Pharmaceuticals shares which in turn could have impacted Marinus Pharmaceuticals's share price.
Marinus Pharmaceuticals share price volatility
Over the last 12 months, Marinus Pharmaceuticals's shares have ranged in value from as little as $1.05 up to $11.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marinus Pharmaceuticals's is 1.125. This would suggest that Marinus Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Marinus Pharmaceuticals overview
Marinus Pharmaceuticals, Inc. , a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.
Frequently asked questions
What percentage of Marinus Pharmaceuticals is owned by insiders or institutions?Currently 0.959% of Marinus Pharmaceuticals shares are held by insiders and 78.709% by institutions. How many people work for Marinus Pharmaceuticals?
Latest data suggests 165 work at Marinus Pharmaceuticals. When does the fiscal year end for Marinus Pharmaceuticals?
Marinus Pharmaceuticals's fiscal year ends in December. Where is Marinus Pharmaceuticals based?
Marinus Pharmaceuticals's address is: 5 Radnor Corporate Center, Radnor, PA, United States, 19087 What is Marinus Pharmaceuticals's ISIN number?
Marinus Pharmaceuticals's international securities identification number is: US56854Q2003 What is Marinus Pharmaceuticals's CUSIP number?
Marinus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 56854Q101
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question